Fundamental Approach to the Treatment of Women with Acute and Chronic Cystitis

Author(s):  
Olga Alekseevna Petrishcheva

Cystitis occurs at least once in a lifetime in one of two women; the highest susceptibility to this disease is noted at the childbearing age — 20–45 years old. Moreover, from 44 % to 82 % of women within a year after the first case of acute uncomplicated cystitis have a relapse, and in 10 % of women the disease takes a chronic course [4]. With age, the likelihood of developing urinary tract infections increases: bacteriuria is diagnosed in 6–10 % of young women and in 25–50 % of people aged 80 years and older. The causative agent of the disease is most often Escherichia coli, less often, Klebsiella, Proteus and Enterococci are detected as a pathogenic agent. Due to the fact that the urethra in women is wider and shorter than in men, women suffer from this ailment much more often, since the infection can get to the bladder quite easily. The issues of diagnosis and treatment of cystitis are in the competence of gynecologists and urologists, but often the initial diagnosis is given already at the appointment of a general practitioner.

Medicine ◽  
2016 ◽  
Vol 95 (36) ◽  
pp. e4663 ◽  
Author(s):  
Jae Heon Kim ◽  
Hwa Yeon Sun ◽  
Tae Hyong Kim ◽  
Sung Ryul Shim ◽  
Seung Whan Doo ◽  
...  

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S794-S794
Author(s):  
Kaitlin Brueggen ◽  
Sara Revolinski ◽  
Mickey Hart ◽  
Magdalena Wrzesinski ◽  
Anne R Daniels

Abstract Background Understanding outpatient antibiotic prescribing practices for urinary tract infections (UTIs) is vital in guiding future stewardship initiatives. Focusing on fluoroquinolones (FQs) is of value as FQs are commonly prescribed, but not recommended as first line therapy by the Infectious Diseases Society of America (IDSA) cystitis treatment guidelines and are also associated with multiple adverse effects. Boxed warnings state FQs should be reserved for patients with no alternative treatment options, due to risk of aortic dissection, C. difficile infection, antimicrobial resistance as well as tendon, joint, muscle, and nervous system damage. Methods This descriptive study assessed rates of guideline concordant empiric FQ prescribing from March 1 to June 30, 2019. Adult women prescribed an oral FQ for acute uncomplicated cystitis at a primary care clinic were included. Men, pregnant or breastfeeding women, and patients with pyelonephritis, urologic abnormality, or antibiotic use in the past 30 days were excluded. The primary outcome was the incidence of IDSA guideline concordance among FQs empirically prescribed. Guideline concordant empiric FQ therapy was defined as correct drug, dose, duration and frequency per IDSA guidelines when no first line drug is indicated due to allergy, adverse effect, previous treatment failure or most recent previous urine culture showing bacterial resistance. Secondary outcomes were mean dose (mg), mean duration (days) and incidence of adverse effects. Results Of 95 FQ prescriptions included, none met the primary outcome definition. Rates of guideline concordance for each component of the primary outcome definition were 6% for drug selection, 38% for dose, 37% for duration, and 99% for frequency. Mean daily doses exceeded guideline recommended doses by 62% and 100% for ciprofloxacin and levofloxacin, respectively. Mean duration was 5 days, 66% longer than 3 days as recommended by IDSA guidelines. Of 66 patients with documented follow up within 30 days, 3 (5%) experienced an adverse effect, and none developed C. difficile infection. Conclusion Current outpatient FQ prescribing for acute uncomplicated cystitis does not align with IDSA guidelines. Multifaceted antimicrobial stewardship initiatives are required to improve appropriate FQ use. Disclosures All Authors: No reported disclosures


2011 ◽  
Vol 79 (10) ◽  
pp. 4250-4259 ◽  
Author(s):  
Drew J. Schwartz ◽  
Swaine L. Chen ◽  
Scott J. Hultgren ◽  
Patrick C. Seed

ABSTRACTUrinary tract infections (UTIs) have complex dynamics, with uropathogenicEscherichia coli(UPEC), the major causative agent, capable of colonization from the urethra to the kidneys in both extracellular and intracellular niches while also producing chronic persistent infections and frequent recurrent disease. In mouse and human bladders, UPEC invades the superficial epithelium, and some bacteria enter the cytoplasm to rapidly replicate into intracellular bacterial communities (IBCs) comprised of ∼104bacteria each. Through IBC formation, UPEC expands in numbers while subverting aspects of the innate immune response. Within 12 h of murine bladder infection, half of the bacteria are intracellular, with 3 to 700 IBCs formed. Using mixed infections with green fluorescent protein (GFP) and wild-type (WT) UPEC, we discovered that each IBC is clonally derived from a single bacterium. Genetically tagged UPEC and a multiplex PCR assay were employed to investigate the distribution of UPEC throughout urinary tract niches over time. In the first 24 h postinfection (hpi), the fraction of tags dramatically decreased in the bladder and kidney, while the number of CFU increased. The percentage of tags detected at 6 hpi correlated to the number of IBCs produced, which closely matched a calculated multinomial distribution based on IBC clonality. The fraction of tags remaining thereafter depended on UTI outcome, which ranged from resolution of infection with or without quiescent intracellular reservoirs (QIRs) to the development of chronic cystitis as defined by persistent bacteriuria. Significantly more tags remained in mice that developed chronic cystitis, arguing that during the acute stages of infection, a higher number of IBCs precedes chronic cystitis than precedes QIR formation.


Sign in / Sign up

Export Citation Format

Share Document